Evi P. Vlachou

Evi P. Vlachou

Auto-generated profile, based on publicly available information

Evi P. Vlachou

European Molecular Biology Laboratory, Molecular Systems Biology Unit, Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
KPKarin D. Prummel
Karin D. Prummel
KWKevin Woods
Kevin Woods
MKMaksim Kholmatov
Maksim Kholmatov
ESEric C. Schmitt
Eric C. Schmitt
EVEvi P. Vlachou
Evi P. Vlachou
BGBorhane Guezguez
Borhane Guezguez
Somatic mutations in hematopoietic stem/progenitor cells (HSPCs) can lead to clonal hematopoiesis of indeterminate potential (CHIP) and progression to myelodysplastic syndromes (MDS). Using single-cell and anatomical profiling of a large cohort of human bone marrow (BM), we show that the HSPC BM niche in CHIP and MDS is undergoing inflammatory remodeling. This includes loss of CXCL12⁺ adipogenic stromal cells and the emergence of a distinct population of inflammatory mesenchymal stromal cells (iMSCs), which arise in CHIP and become more prevalent in MDS. Functional studies in primary BM HSPC-MSC co-cultures reveals that healthy aged and CHIP HSPCs activate stromal support, while MDS HSPCs fail to do so. In contrast, MDS blasts further suppress HSPC support and trigger inflammation, indicating disease-stage-specific stromal disruption. In parallel, we show that iMSCs retain partial support and angiogenic potential in MDS, coinciding with expanded BM vasculature. Additionally, we identify IFN-responsive T cells that preferentially interact with iMSCs, potentially reinforcing local inflammation. These findings position iMSCs as central mediators of early BM niche dysfunction and potential therapeutic targets for intercepting pre-malignant hematopoiesis.

26 May 2025 in Nature Methods
Verified
Journal Article
Open access
PDF file
SLSara Lobato-Moreno
Sara Lobato-Moreno
UYUmut Yildiz
Umut Yildiz
ACAnnique Claringbould
Annique Claringbould
NSNila H. Servaas
Nila H. Servaas
EVEvi P. Vlachou
Evi P. Vlachou
JZJudith B. Zaugg
Judith B. Zaugg
Enhancers and transcription factors (TFs) are crucial in regulating cellular processes. Current multiomic technologies to study these elements in gene regulatory mechanisms lack multiplexing capability and scalability. Here we present single-cell ultra-high-throughput multiplexed sequencing (SUM-seq) for co-assaying chromatin accessibility and gene expression in single nuclei. SUM-seq enables profiling hundreds of samples at the million cell scale and outperforms current high-throughput single-cell methods. We demonstrate the capability of SUM-seq to (1) resolve temporal gene regulation of macrophage M1 and M2 polarization to bridge TF regulatory networks and immune disease genetic variants, (2) define the regulatory landscape of primary T helper cell subsets and (3) dissect the effect of perturbing lineage TFs via arrayed CRISPR screens in spontaneously differentiating human induced pluripotent stem cells. SUM-seq offers a cost-effective, scalable solution for ultra-high-throughput single-cell multiomic sequencing, accelerating the unraveling of complex gene regulatory networks in cell differentiation, responses to perturbations and disease studies.

26 February 2026 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
UYUmut Yildiz
Umut Yildiz
SLSara Lobato-Moreno
Sara Lobato-Moreno
ACAnnique Claringbould
Annique Claringbould
HBHanke Gwendolyn Bauersachs
Hanke Gwendolyn Bauersachs
NSNila H. Servaas
Nila H. Servaas
MMMikael Marttinen
Mikael Marttinen